More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...

Common antiplatelet medications include aspirin, which inhibits the enzyme cyclooxygenase-1 (COX-1), and clopidogrel, which blocks the P2Y12 receptor on platelets. By preventing platelets from ...

The following is a summary of “Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: ...

Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its superior antiplatelet potency compared with ...

Singh, A. , Sinha, R. , Saran, M. , Kazmi, D. , Gupta, H. and Seth, G. (2025) Efficacy and Safety of Dual Antiplatelet Therapy in High-Risk, Post-Percutaneous Coronary Intervention Patients beyond One ...

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic ...

De-escalating dual antiplatelet therapy from from aspirin plus ticagrelor to aspirin plus clopidogrel after primary ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...